Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Rating of “Buy” by Brokerages

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has received an average recommendation of “Buy” from the seven analysts that are currently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $15.57.

A number of research firms have recently issued reports on FULC. The Goldman Sachs Group upgraded Fulcrum Therapeutics from a “neutral” rating to a “buy” rating and increased their target price for the company from $6.00 to $15.00 in a report on Monday, May 13th. Piper Sandler increased their target price on shares of Fulcrum Therapeutics from $13.00 to $15.00 and gave the company an “overweight” rating in a research note on Wednesday, February 28th. Oppenheimer cut their price target on shares of Fulcrum Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Tuesday, May 14th. HC Wainwright restated a “buy” rating and issued a $17.00 price objective on shares of Fulcrum Therapeutics in a research report on Tuesday, May 14th. Finally, Royal Bank of Canada initiated coverage on Fulcrum Therapeutics in a report on Wednesday, March 13th. They set an “outperform” rating and a $14.00 target price on the stock.

Institutional Trading of Fulcrum Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. grew its holdings in Fulcrum Therapeutics by 348.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,150 shares of the company’s stock valued at $48,000 after buying an additional 5,556 shares in the last quarter. Capstone Investment Advisors LLC acquired a new stake in shares of Fulcrum Therapeutics in the 4th quarter valued at about $68,000. SG Americas Securities LLC bought a new position in shares of Fulcrum Therapeutics in the first quarter valued at $115,000. Brown Wealth Management LLC bought a new stake in shares of Fulcrum Therapeutics in the 3rd quarter worth $111,000. Finally, Algert Global LLC bought a new stake in Fulcrum Therapeutics during the third quarter worth $138,000. Institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Trading Up 4.7 %

NASDAQ:FULC opened at $6.68 on Friday. The firm has a market cap of $415.19 million, a price-to-earnings ratio of -4.18 and a beta of 2.34. Fulcrum Therapeutics has a twelve month low of $3.03 and a twelve month high of $13.70. The company has a 50-day moving average of $7.50 and a 200-day moving average of $7.96.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.01. Fulcrum Therapeutics had a negative return on equity of 40.60% and a negative net margin of 3,470.05%. On average, research analysts forecast that Fulcrum Therapeutics will post -1.24 earnings per share for the current year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.